10-Q: Aytu BioPharma Q1 2026: EXXUA Launch Nears, Revenue Dips

Aytu BioPharma reports a net income of $1.965 million for Q1 fiscal 2026, driven by a derivative warrant liabilities gain, as it prepares for the anticipated launch of its major depressive disorder treatment, EXXUA.

Summary

• Net income for the three months ended September 30, 2025, was $1.965 million, up from $1.474 million in the prior year period.
• Net revenue decreased by $2.7 million, or 16%, to $13.888 million for Q1 fiscal 2026 compared to $16.574 million in Q1 fiscal 2025, primarily due to a $3.3 million one-time increase in ADHD Portfolio net revenue in Q1 fiscal 2025.
• Gross profit decreased by $2.8 million, or 23%, to $9.186 million, with gross profit percentage falling from 72% to 66%.
• Operating expenses decreased by $2.225 million, or 17%, to $10.690 million, primarily due to reduced R&D, amortization, and restructuring costs.
• Loss from operations increased to $(1.504) million from $(0.930) million.
• A significant derivative warrant liabilities gain of $3.784 million was recognized, up from $2.880 million in the prior year, primarily due to a decrease in stock price.
• Net cash used in operating activities improved to $(0.6) million from $(1.2) million.
• The company anticipates launching EXXUA, a novel first-in-class selective serotonin 5HT1a receptor agonist for MDD, in the second fiscal quarter of 2026.
• The Consumer Health business was divested on July 31, 2024, and is reported as discontinued operations.
• Outstanding common stock as of November 1, 2025, was 10,188,208 shares.

Sentiment

Score: 5

Explanation: While the company reported net income and improved cash flow from operations, the core revenue and gross profit declined, and the net income was significantly boosted by a non-cash derivative warrant liabilities gain. The upcoming EXXUA launch is a major positive, but its success is yet to be realized, and the company faces ongoing patent litigation and macroeconomic headwinds. The overall sentiment is neutral to slightly cautious, reflecting both strategic progress and operational challenges.

Positives

• Net income increased to $1.965 million for Q1 fiscal 2026 from $1.474 million in Q1 fiscal 2025.
• Operating expenses decreased by $2.225 million (17%) due to suspension of development programs, lower amortization, and completed restructuring.
• Net cash used in operating activities improved to $(0.6) million from $(1.2) million in the prior year.
• Successful divestiture of the Consumer Health business, streamlining operations to focus on core prescription products.
• Anticipated launch of EXXUA in Q2 fiscal 2026, which is believed to be a major growth catalyst in the $22 billion U.S. MDD market.
• EXXUA is noted as the only antidepressant acting on serotonin receptors that does not carry a label warning about sexual dysfunction risk.
• International collaboration agreements for ADHD products with Medomie (Israel/Palestinian Authority) and Lupin (Canada) are in place.
• The company was in compliance with covenants under the Eclipse Agreement as of September 30, 2025.
• Disclosure controls and procedures were effective as of September 30, 2025.

Negatives

• Net revenue decreased by $2.7 million (16%) to $13.888 million, primarily due to a non-recurring revenue adjustment in the prior year, indicating a weaker underlying sales performance.
• Gross profit decreased by $2.8 million (23%) and gross profit percentage declined from 72% to 66%.
• Loss from operations increased to $(1.504) million from $(0.930) million.
• ADHD Portfolio net revenue decreased by $2.108 million.
• Pediatric Portfolio net revenue decreased by $0.578 million.
• Diluted net loss per share from continuing operations was $(0.08) compared to $(0.20) in the prior year, still a loss.
• Ongoing patent infringement lawsuit against Granules Pharmaceuticals regarding Adzenys, with a trial date moved to January 11, 2027.
• Experience of inflationary pressures, economic uncertainty, and supply chain disruptions (raw materials, increased costs for tariffs, energy, logistics, labor).
• Section 382 limitation on NOL utilization and existing valuation allowances continue to impact income tax expense.

Risks

• Competitive Landscape: Potential impact from entry of generic competitors, payor pressures, and new branded entrants.
• Supply Chain Disruptions: Ongoing issues related to sourcing raw materials, increased costs due to tariffs, energy, logistics, and labor.
• Trade Wars: Potential adverse effects on markets, suppliers, costs, and availability of energy/materials, or further supply chain disruptions.
• Patent Infringement Litigation: Ongoing lawsuit against Granules Pharmaceuticals regarding Adzenys, which could impact future revenue if Granules successfully markets a generic version.
• Regulatory Approvals for International Markets: Medomie and Lupin are responsible for seeking local regulatory approvals and marketing authorizations for ADHD products, which is expected to occur over the next 24 months, introducing uncertainty.
• EXXUA Commercialization Success: The Second Payment of $3.0 million (potentially $5.0 million) and future milestone payments are contingent on EXXUA's commercial success and net revenue thresholds.
• Warrant Liabilities Volatility: Changes in the fair value of derivative warrant liabilities, driven by stock price fluctuations, can significantly impact reported income/loss.
• NOL Utilization Limitations: Section 382 of the IRC limits the company's ability to offset post-ownership change taxable income with pre-ownership change net operating loss carryforwards, increasing future tax liability.
• General Economic Conditions: Broader economic and financial market conditions could impact the business.

Future Outlook

The company anticipates launching EXXUA, a novel first-in-class selective serotonin 5HT1a receptor agonist for the treatment of major depressive disorder (MDD), in the second fiscal quarter of 2026, expecting it to be a major growth catalyst. It will continue to focus on commercializing innovative prescription products for CNS conditions, including ADHD. International collaborations with Medomie (Israel/Palestinian Authority) and Lupin (Canada) are expected to lead to local regulatory approvals and marketing authorizations for ADHD products over the next 24 months. The company aims to accelerate commercial business growth and achieve positive operating cash flows. Inflationary pressures, increased costs, and supply chain disruptions are expected to continue throughout fiscal 2026 and into fiscal 2027.

Management Comments

• "EXXUA has the potential to serve as a major growth catalyst for us, and we anticipate launching EXXUA in the second quarter of fiscal 2026 as a centerpiece of our commercial efforts."
• "We believe it can become a very important treatment option for the estimated 21 million Americans affected by MDD."
• "Importantly, we believe that EXXUA is the only antidepressant acting on serotonin receptors that does not carry a label warning about the risk of sexual dysfunction."
• "We are focusing our efforts on accelerating the growth of our commercial business and achieving positive operating cash flows."
• "We plan to vigorously enforce our intellectual property rights related to Adzenys."

Industry Context

Aytu BioPharma is strategically shifting its focus to complex CNS diseases, particularly with the upcoming launch of EXXUA for Major Depressive Disorder (MDD). This positions the company to compete in a substantial U.S. prescription MDD market valued over $22 billion, addressing significant unmet needs, especially regarding side effects like sexual dysfunction associated with current antidepressants. The divestiture of its Consumer Health business and suspension of clinical development programs align with a broader industry trend of pharmaceutical companies streamlining operations to focus on high-potential, specialized therapeutic areas. The company's efforts in ADHD and international collaborations reflect a strategy to diversify revenue streams and expand market reach for existing products, while navigating challenges like generic competition and supply chain pressures common in the pharmaceutical sector.

Comparison to Industry Standards

• EXXUA is positioned as a novel first-in-class selective serotonin 5HT1a receptor agonist, differentiating it from SSRIs and other existing antidepressants in the over $22 billion U.S. MDD market.
• The company highlights EXXUA as the only antidepressant acting on serotonin receptors that does not carry a label warning about the risk of sexual dysfunction, addressing a key unmet need compared to many current therapeutics.
• The ongoing patent infringement lawsuit against Granules Pharmaceuticals regarding Adzenys is a common occurrence in the pharmaceutical industry as generic manufacturers challenge branded drug patents.
• The company's gross profit percentage of 66% for the quarter, while down from 72% in the prior year, should be assessed against industry averages for specialty pharmaceuticals, which can vary widely based on product mix, pricing power, and manufacturing costs.

Corporate Governance

Legal Proceedings

• Granules Paragraph IV Patent Infringement: Received a Paragraph IV Certification Notice Letter from Granules Pharmaceuticals, Inc. on October 31, 2024, stating intent to market a generic version of Adzenys before patent expiration. A patent infringement lawsuit was filed on December 11, 2024, triggering a 30-month stay on FDA approval. The trial date has been moved to January 11, 2027.
• Revive Investing Lawsuit: Named as a nominal plaintiff in a lawsuit by shareholders against Armistice Capital Master Fund, Ltd. for short swing trading profits. A jury returned a verdict of no liability on January 29, 2025. Plaintiffs filed an appeal on March 6, 2025. The company states this case will not have a materially adverse effect on its financial condition, results of operations, or cash flows.

Stakeholder Impact

• Shareholders: Potential for future growth from EXXUA launch, but also dilution risk from warrants and shelf registration. Ongoing patent litigation introduces uncertainty. Net income improved, but revenue declined.
• Employees: Suspension of clinical development programs and divestiture of Consumer Health business indicate a strategic realignment, potentially impacting roles in those areas. Equity incentive plans are in place.
• Customers: Anticipated launch of EXXUA offers a new treatment option for MDD patients, potentially addressing unmet needs regarding side effects. Continued availability of ADHD and Pediatric Portfolio products.
• Suppliers/CMOs: Continued reliance on contract manufacturing organizations (CMOs) for product manufacturing and testing. Supply chain disruptions could affect relationships and costs.
• Creditors: Compliance with Eclipse Agreement covenants maintained. Debt obligations are being managed, with some paydowns.

Next Steps

• Launch EXXUA in the second fiscal quarter of 2026.
• Continue commercializing innovative prescription products for CNS conditions, including ADHD.
• Medomie and Lupin to seek local regulatory approvals and marketing authorizations for ADHD products in Israel/Palestinian Authority and Canada over the next 24 months.
• Vigorously enforce intellectual property rights related to Adzenys in the ongoing patent infringement lawsuit against Granules Pharmaceuticals, with trial rescheduled for January 11, 2027.
• Assess the potential impact of the One Big Beautiful Bill Act (OBBBA) on business, financial condition, results of operations, and future plans, and provide updates in future SEC filings.
• Continue to evaluate potential strategic transactions and business combinations to enhance stockholder value.
• Repay the remaining $1.3 million of the Eclipse Incremental Advance with monthly payments of $125,000 until reduced to $0.

Key Dates

Recommendation

The company is in a transitional phase, having divested non-core assets and suspended R&D to focus on commercialization. The upcoming launch of EXXUA is a significant potential catalyst, targeting a large market with a differentiated product profile. However, the recent quarter showed a decline in net revenue and gross profit from continuing operations, even with an improved net income driven by a non-cash gain. The ongoing patent litigation for Adzenys and macroeconomic headwinds present notable risks. Investors should hold to observe the initial commercial performance of EXXUA and the resolution of legal and economic uncertainties before making further investment decisions.

Keywords

Aytu BioPharma, EXXUA, Major Depressive Disorder, MDD, ADHD, Pharmaceuticals, Biopharma, SEC Filing, 10-Q, Financial Results, Q1 2026, Gepirone, Drug Launch, Warrants, Patent Litigation, Sarbanes-Oxley, CNS diseases, Commercialization Agreement